<DOC>
	<DOCNO>NCT01747330</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Creon micro child young four year pancreatic exocrine insufficiency .</brief_summary>
	<brief_title>Evaluation Safety Tolerability Creon Micro Children Younger Than Four Years With Pancreatic Exocrine Insufficiency</brief_title>
	<detailed_description>A prospective open-label , multi-center study evaluate safety tolerability Creon Micro pediatric subject least one month less four year age Pancreatic Exocrine Insufficiency ( PEI ) due Cystic Fibrosis ( CF ) . Referring European Medicines Agency ( EMEA ) pediatric age criterion purpose study , subject categorize infant toddler ( &lt; 2 year ) child , ( 2 year &lt; 4 year ) . In total , 40 subject enrol ( 20 subject age subgroup ) . Subjects receive prescribe pancreatic enzyme supplementation individual dose start treatment Creon Micro , subject pancreatic enzyme supplementation start study . Subjects treat Creon Micro study . The treatment duration 3 month .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Children young four year confirm cystic fibrosis diagnosis body weight least 2 kilogram Ileus acute abdomen history fibrosing colonopathy history distal ileal obstruction without surgery solid organ transplant surgery affect large bowel , appendectomy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>cystic fibrosis</keyword>
</DOC>